Cyclopyrronium bromide is an anticholinergic agent, discovered by Robins Company, Inc. Ex vivo study has demonstrated that the compound was effective in inhibiting gastrointestinal motility in isolated guinea pig ileum.

Deterenol is a beta-adrenoceptor agonist. It is an effective nonmydriatic and nonmiotic hypotensive agent, which can be used in antiglaucoma treatment.

Azipramine, an antidepressant, that never been marketed.

Etiprednol dicloacetate (BNP-166; ethyl-17alpha-dichloroacetoxy-11beta-hydroxyandrosta-1,4-diene-3-one-17beta-carboxylate) is a new soft steroid. The compound proved to be a dissociated glucocorticoid, showing a reduction in transactivating activity while preserving transrepressive abilities. The compound effectively decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture. The significant local effect of the compound will very likely be accompanied by a drastically reduced systemic activity indicating an encouraging selectivity of the pharmacological action of etiprednol dicloacetate. Etiprednol dicloacetate had been in a clinical trial for the treatment of allergic rhinitis, asthma and Crohn's disease. However, development has been discontinued.

Antazonite (R 6438) is an anthelmintic agent. When given orally to chickens in a dose of 160 mg/Kg body weight, all Ascaridia sp., all Hetevakis sp., and about 30% Capillaria sp. are expelled within 48 hr. It is supposed that the anthelmintic activity of Antazonite is due to its major metabolite, R 8141. R 6438 is active as an anthelmintic in poultry, but not in rats. Its metabolite, R 8141, is active in both species.

Anilopam is an opioid analgesic of the benzazepine class. It is an opioid receptor agonist.

Tecarfarin (also known as ATI-5923), an anticoagulant, is a vitamin K reductase antagonist. Tecarfarin is participating in phase III clinical trials for the treatment of thromboembolism and thrombosis. On March 11, 2019, Espero BioPharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin. Tecarfarin is metabolized by esterases, escaping metabolism by the cytochrome P450 system and thereby avoiding cytochrome P450-mediated drug-drug or drug-food interactions as well as genetic variations found in the cytochrome P450 system.